Lacnotuzumab

N/A

Report date: 2025/06/05 20:00:13

Base Information

Drug NameLacnotuzumab
Drug Alias NameMCS-110
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMacrophage Colony Stimulating Factor 1 inhibitors
TargetsMacrophage Colony Stimulating Factor 1
Therapy Area/IndicationsBone metastasesProstatic NeoplasmsEndometrial Neoplasms +[11
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSingapore +[18
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsBone metastasesProstatic NeoplasmsEndometrial Neoplasms +[11

Other Information

ATC CodeN/A
Related LinksN/A